We are live on ! Find out more
ORKA

Oruka Therapeutics
ORKA

16 hedge funds and large institutions have $6.17M invested in Oruka Therapeutics in 2017 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

7% more funds holding

Funds holding: 15 → 16 (+1)

0.06% less ownership

Funds ownership: 0.25% → 0.2% (-0.06%)

50% less capital invested

Capital invested by funds: $12.3M → $6.17M (-$6.1M)

Holders
16
Holders Change
+1
Holders Change %
+6.67%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$300K
2
SM
Sabby Management
Florida
+$165K
3
RA
Royce & Associates
New York
+$90.3K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$63.3K
5
Deutsche Bank
Deutsche Bank
Germany
+$46.6K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$39K
2
ACP
Aveo Capital Partners
Colorado
-$711
3
Morgan Stanley
Morgan Stanley
New York
-$356
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$1.68M – – –
Franklin Resources
2
Franklin Resources
California
$1.34M – – –
VMI
3
VHCP Management II
New York
$1.24M – – –
TCM
4
Tekla Capital Management
Massachusetts
$892K – – –
Renaissance Technologies
5
Renaissance Technologies
New York
$272K +$300K +844 +335%
RA
6
Royce & Associates
New York
$258K +$90.3K +254 +30%
Vanguard Group
7
Vanguard Group
Pennsylvania
$122K +$63.3K +178 +53%
SM
8
Sabby Management
Florida
$110K +$165K +463 New
ACP
9
Aveo Capital Partners
Colorado
$107K -$711 -2 -0.5%
Deutsche Bank
10
Deutsche Bank
Germany
$101K +$46.6K +131 +47%
VF
11
Virtu Financial
New York
$20K +$28.8K +81 New
Northern Trust
12
Northern Trust
Illinois
$13K – – –
Cambridge Investment Research Advisors
13
Cambridge Investment Research Advisors
Iowa
$12K – – –
UBS Group
14
UBS Group
Switzerland
$5K +$6.76K +19 New
Bank of America
15
Bank of America
North Carolina
$1K – – –
BlackRock
16
BlackRock
New York
$1K – – –
Goldman Sachs
17
Goldman Sachs
New York
– -$39K -75 Closed
Morgan Stanley
18
Morgan Stanley
New York
– -$356 -1 Closed

ORKA Hedge Fund Activity: Q3 2017 in Review

16 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q3 2017, worth a combined $6.17M — down 50% from $12.3M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new ORKA positions and 2 closed out — a net gain of 1 holder — while 4 added to existing stakes and 1 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $300K. The largest seller was Goldman Sachs, exiting entirely with an estimated $39K sold.

  • 16 institutional investors held Oruka Therapeutics (ORKA) as of Q3 2017, up from 15 in Q2 2017.
  • Funds reported $6.17M of Oruka Therapeutics stock for Q3 2017, down 50% quarter-over-quarter.
  • 3 funds opened new Oruka Therapeutics positions in Q3 2017 and 2 closed out, a net change of +1 holder.
  • The largest Oruka Therapeutics buyer in Q3 2017 was Renaissance Technologies, an estimated $300K added.
  • The largest Oruka Therapeutics seller in Q3 2017 was Goldman Sachs, an estimated $39K sold.

Based on aggregated 13F filings for Q3 2017.